Literature DB >> 15895401

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

Giorgio Bedogni1, Lucia Miglioli, Flora Masutti, Claudio Tiribelli, Giulio Marchesini, Stefano Bellentani.   

Abstract

The prevalence of and the risk factors for fatty liver have not undergone a formal evaluation in a representative sample of the general population. We therefore performed a cross-sectional study in the town of Campogalliano (Modena, Italy), within the context of the Dionysos Project. Of 5,780 eligible persons aged 18 to 75 years, 3,345 (58%) agreed to participate in the study. Subjects with suspected liver disease (SLD), defined on the basis of elevated serum alanine aminotransferase (ALT) and gamma-glutamyl-transferase (GGT) activity, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)-RNA positivity, were matched with randomly selected subjects of the same age and sex without SLD. A total of 311 subjects with and 287 without SLD underwent a detailed clinical, laboratory, and anthropometrical evaluation. Fatty liver was diagnosed by ultrasonography, and alcohol intake was assessed by using a 7-day diary. Multinomial logistic regression was used to detect risk factors for normal liver versus nonalcoholic fatty liver disease (NAFLD) and for alcoholic fatty liver (AFLD) versus NAFLD. The prevalence of NAFLD was similar in subjects with and without SLD (25 vs. 20%, P = .203). At multivariable analysis, normal liver was more likely than NAFLD in older subjects and less likely in the presence of obesity, hyperglycemia, hyperinsulinemia, hypertriglyceridemia, and systolic hypertension; AFLD was more likely than NAFLD in older subjects, males, and in the presence of elevated GGT and hypertriglyceridemia, and less likely in the presence of obesity and hyperglycemia. In conclusion, NAFLD is highly prevalent in the general population, is not associated with SLD, but is associated with many features of the metabolic syndrome.

Entities:  

Mesh:

Year:  2005        PMID: 15895401     DOI: 10.1002/hep.20734

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  376 in total

1.  Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease.

Authors:  Bernd Schnabl; Barbara Czech; Daniela Valletta; Thomas S Weiss; Georgi Kirovski; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2011-09-22

2.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

3.  Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Mitsuhito Koizumi; Shinya Furukawa; Teruhisa Ueda; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-02-14       Impact factor: 7.527

4.  Obesity and microvascular invasion in hepatocellular carcinoma.

Authors:  Abby B Siegel; Shuang Wang; Judith S Jacobson; Dawn L Hershman; Emerson A Lim; Jeanette Yu; Lauren Ferrante; Kalpana M Devaraj; Helen Remotti; Shannon Scrudato; Karim Halazun; Jean Emond; Lorna Dove; Robert S Brown; Alfred I Neugut
Journal:  Cancer Invest       Date:  2010-12       Impact factor: 2.176

Review 5.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

Review 8.  Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.

Authors:  Ludovico Abenavoli; Natasa Milic; Valentina Peta; Francesco Alfieri; Antonino De Lorenzo; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Limited therapeutic efficacy of thrombopoietin on the regeneration of steatotic livers.

Authors:  Kerstin Abshagen; Franziska Mertens; Christian Eipel; Brigitte Vollmar
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

Review 10.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.